ABVC BioPharma, Inc.(ABVC),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

ABVC ABVC BioPharma, Inc.

Market Closed 05-10 16:00:00 EDT

1.06

-0.04

-3.64%

盘后1.06

+0.000.00%

19:52 EDT

High1.09	Low1.05	Vol207.67K
Open1.08	D1 Closing1.10	Amplitude3.64%
Mkt Cap11.17M	Tradable Cap7.21M	Total Shares10.53M
T/O221.40K	T/O Rate3.05%	Tradable Shares6.80M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

{"stockData":{"symbol":"ABVC","market":"US","secType":"STK","nameCN":"ABVC BioPharma, Inc.","latestPrice":1.06,"timestamp":1715371200000,"preClose":1.1,"halted":0,"volume":207665,"hourTrading":{"tag":"盘后","latestPrice":1.06,"preClose":1.06,"latestTime":"19:52 EDT","volume":2106,"amount":2246.72,"timestamp":1715385122176},"delay":0,"floatShares":6800153,"shares":10533868,"eps":-2.43,"marketStatus":"Market Closed","change":-0.04,"latestTime":"05-10 16:00:00 EDT","open":1.08,"high":1.09,"low":1.05,"amount":221400.66916100003,"amplitude":0.036364,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-2.43,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Market Trading","tradingStatus":1,"beginTime":1715587200000},"marketStatusCode":7,"adr":0,"listingDate":1627963200000,"exchange":"NASDAQ","adjPreClose":1.1,"preHourTrading":{"tag":"盘前","latestPrice":1.07,"preClose":1.1,"latestTime":"09:29 EDT","volume":7841,"amount":8405.6492284,"timestamp":1715347782206},"postHourTrading":{"tag":"盘后","latestPrice":1.06,"preClose":1.06,"latestTime":"19:52 EDT","volume":2106,"amount":2246.72,"timestamp":1715385122176},"volumeRatio":0.3128934105218564},"requestUrl":"/m/hq/s/ABVC","defaultTab":"news","newsList":[{"id":"2434864543","title":"Xenon Pharmaceuticals Inc (XENE) Reports Increased Losses in Q1 2024, Despite Advancements in ...","url":"https://stock-news.laohu8.com/highlight/detail?id=2434864543","media":"GuruFocus.com","top":-1,"share":"https://ttm.financial/m/news/2434864543?lang=en_us&edition=fundamental","pubTime":"2024-05-11 00:56","pubTimestamp":1715360169,"startTime":"0","endTime":"0","summary":"Net Loss: Reported a net loss of $47.9 million for Q1 2024, an increase from $41.7 million in Q1 2023, exceeding the estimated net loss of $46.64 million.EPS: Reported an EPS of -$0.62, slightly better than the estimated EPS of -$0.66.Revenue: Revenue data not explicitly mentioned, aligning with the estimated revenue of $0.00 million.Cash Reserves: Cash and cash equivalents, including marketable securities, totaled $885.4 million as of March 31, 2024, down from $930.9 million at the end of 2023.R&D Expenses: Research and development expenses increased to $44.3 million in Q1 2024 from $39.5 million in Q1 2023, reflecting ongoing investment in clinical programs.General and Administrative Expenses: Rose to $14.8 million in Q1 2024 from $9.5 million in the same period last year, driven by higher personnel costs and professional fees.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/xenon-pharmaceuticals-inc-xene-reports-165609857.html","is_publish_highlight":false,"gpt_icon":0},{"id":"2434909887","title":"Why Axsome Therapeutics Is A Promising Stock Pick In CNS Treatments","url":"https://stock-news.laohu8.com/highlight/detail?id=2434909887","media":"seekingalpha","top":-1,"share":"https://ttm.financial/m/news/2434909887?lang=en_us&edition=fundamental","pubTime":"2024-05-10 16:36","pubTimestamp":1715330218,"startTime":"0","endTime":"0","summary":"Axsome Therapeutics develops treatments for CNS conditions, with two commercial products: Auvelity for major depressive disorders and Sunosi for sleep disorders.The company has a diverse pipeline targ","market":"sh","thumbnail":"https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1215516118/image_1215516118.jpg","type":0,"news_type":0,"thumbnails":["https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1215516118/image_1215516118.jpg"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://seekingalpha.com/article/4691748-axsome-therapeutics-promising-stock-pick-cns-treatments","is_publish_highlight":false,"gpt_icon":0},{"id":"2434772007","title":"Maintained Buy Rating on ITCI Shares Amidst Strong Caplyta Revenue and Positive MDD Study Outlook","url":"https://stock-news.laohu8.com/highlight/detail?id=2434772007","media":"TIPRANKS","top":-1,"share":"https://ttm.financial/m/news/2434772007?lang=en_us&edition=fundamental","pubTime":"2024-05-10 14:08","pubTimestamp":1715321281,"startTime":"0","endTime":"0","summary":"In a report released on May 8, Graig Suvannavejh from Mizuho Securities reiterated a Buy rating on Intra-Cellular Therapies (ITCI – Research Report...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/maintained-buy-rating-on-itci-shares-amidst-strong-caplyta-revenue-and-positive-mdd-study-outlook?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["earning"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/maintained-buy-rating-on-itci-shares-amidst-strong-caplyta-revenue-and-positive-mdd-study-outlook?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"gpt_icon":0},{"id":"2434011534","title":"BRIEF-Abvc Collaboration With Oncox Biopharma, Abvc Expecting Aggregate Income Of $13.75 Million And Royalties Of Up To $12.50 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2434011534","media":"Reuters","top":-1,"share":"https://ttm.financial/m/news/2434011534?lang=en_us&edition=fundamental","pubTime":"2024-05-09 23:09","pubTimestamp":1715267352,"startTime":"0","endTime":"0","summary":"May 9  - ABVC Biopharma Inc   :   * ABVC BIOPHARMA INC - COLLABORATION BETWEEN ABVC AND ONCOX BIOPHARMA, ABVC EXPECTING AGGREGATE INCOME OF $13.75 MILLION AND ROYALTIES OF UP TO $12.50 MILLION   * ABVC BIOPHARMA- GRANTS ONCOX EXCLUSIVE RIGHTS FOR ONE OF ABVC’S FOUR PRODUCTS IN ITS ONCOLOGY PIPELINE TO DEVELOP, MANUFACTURE, COMMERCIALIZE BLEX 404Source text for Eikon:    Further company coverage:    ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"gpt_icon":0},{"id":"2434015487","title":"Combination Therapy Holds Promise for Pancreatic Cancer Treatment: A Milestone Collaboration Between ABVC and OncoX, ABVC Expecting Aggregate Income of $13.75M and Royalties of up to $12.50M","url":"https://stock-news.laohu8.com/highlight/detail?id=2434015487","media":"NewMediaWire","top":-1,"share":"https://ttm.financial/m/news/2434015487?lang=en_us&edition=fundamental","pubTime":"2024-05-09 21:35","pubTimestamp":1715261727,"startTime":"0","endTime":"0","summary":"The United States Food & Drug Administration  has approved four INDs: ABV-1501  for Triple Negative Breast Cancer , ABV-1519  for Non-Small Cell Lung Cancer , ABV-1702  for Myelodysplastic Syndrome , and ABV-1703  for Pancreatic Cancer Therapy. The Investigational New Drug  application for ABV-1703 proposed the clinical investigation of BLEX 404 as a Combination Therapy Drug with Chemotherapy. The active ingredient of BLEX 404 is the -glucan extracted from Grifola frondosa , an edible fungus with high medical and commercial values in Asia; it contains various bioactive constituents such as polysaccharides, pyrrole alkaloids, ergosterol, etc., and has been widely served as functional foods for a long time in daily life.[1]","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/Sj4hR__Ym50.qhhXl4bcxA--~B/aD0xMjI7dz0xNDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/newsmediawire_165/0a225db1dfc4b8bb37baec245393aef9","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/Sj4hR__Ym50.qhhXl4bcxA--~B/aD0xMjI7dz0xNDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/newsmediawire_165/0a225db1dfc4b8bb37baec245393aef9"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/combination-therapy-holds-promise-pancreatic-133527110.html","is_publish_highlight":false,"gpt_icon":0},{"id":"2434895705","title":"Supernus Announces First Quarter 2024 Financial Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2434895705","media":"GlobeNewswire","top":-1,"share":"https://ttm.financial/m/news/2434895705?lang=en_us&edition=fundamental","pubTime":"2024-05-09 04:05","pubTimestamp":1715198700,"startTime":"0","endTime":"0","summary":"Net sales of Qelbree increased 75% to $45.1 million compared to first quarter 2023.Total revenues were $143.6 million. Total revenues excluding Trokendi XR and Oxtellar XR net product sales  increased 12% to $100.7 million compared to first quarter 2023.Operating loss was $(3.2) million. Adjusted operating earnings  was $22.3 million.Reiterates full year 2024 financial guidance, including total revenue guidance of $580million to $620million, operating loss guidance of $ million to $0 million, and adjusted operating earnings  guidance of $80million to $110million.ROCKVILLE, Md., May 08, 2024  -- Supernus Pharmaceuticals, Inc. , a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system  diseases, today announced financial results for the first quarter of 2024 and associated Company developments.\"We are pleased to announce another strong quarter for Qelbree, which delivered robust growth of 75% in net sales compared to the s","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/rJ24rXQDLktslEmoKvEp8w--~B/aD05Mzt3PTM2NjthcHBpZD15dGFjaHlvbg--/https://media.zenfs.com/en/globenewswire.com/314efe0f659fa701d50fbe1a11762b7a","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/rJ24rXQDLktslEmoKvEp8w--~B/aD05Mzt3PTM2NjthcHBpZD15dGFjaHlvbg--/https://media.zenfs.com/en/globenewswire.com/314efe0f659fa701d50fbe1a11762b7a"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/supernus-announces-first-quarter-2024-200500433.html","is_publish_highlight":false,"gpt_icon":0},{"id":"2434677518","title":"Lifeway Foods® Applauds New Research Examining the Impact of Probiotics in Dairy Kefir on the Microbiome in Children with ADHD","url":"https://stock-news.laohu8.com/highlight/detail?id=2434677518","media":"PR Newswire","top":-1,"share":"https://ttm.financial/m/news/2434677518?lang=en_us&edition=fundamental","pubTime":"2024-05-09 00:00","pubTimestamp":1715184000,"startTime":"0","endTime":"0","summary":"Study protocol suggests consumption of probiotics in kefir positively alters the composition of the gut microbiome and may be linked to behavioral effects and improvements in sleep. MORTON GROVE, Ill., May 8, 2024 /PRNewswire/ -- Lifeway Foods, Inc., a leading U.S. supplier of kefir and fermented probiotic products that support the microbiome, applauds the recent studyprotocol titled, \"Randomised controlled trial of the effects of kefir on behaviour, sleep and the microbiome in children with ADHD: a study protocol,\" published by the British Medical Journal  Open Journal. The trial will test diet-based intervention targeting gut health to support the wellbeing of children with ADHD, as previous research has suggested that daily consumption of the probiotics in dairy kefir can positively alter the composition of the microbiome, thus leading to a reduction in ADHD symptoms and improvements in sleep.1. Forward-Looking Statements This release  contains \"forward-looking statements\" as define","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/if4mmUXY0anY77bSforkYA--~B/aD0xOTg7dz00MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/prnewswire.com/e320b8227987eaab07198f1f292dc22e","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/if4mmUXY0anY77bSforkYA--~B/aD0xOTg7dz00MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/prnewswire.com/e320b8227987eaab07198f1f292dc22e"],"rights":{"source":"yahoofinance","url":"https://finance.yahoo.com/news/lifeway-foods-applauds-research-examining-160000499.html","rn_cache_url":null,"customStyle":"img, svg { display: none !important; }","selectors":"article","filters":"","directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/lifeway-foods-applauds-research-examining-160000499.html","is_publish_highlight":false,"gpt_icon":0},{"id":"2433785168","title":"M8 Pharmaceuticals, an Acino company, signs an exclusive licensing agreement with Supernus for Qelbree® (Viloxazine XR) in Latin America","url":"https://stock-news.laohu8.com/highlight/detail?id=2433785168","media":"PR Newswire","top":-1,"share":"https://ttm.financial/m/news/2433785168?lang=en_us&edition=fundamental","pubTime":"2024-05-07 22:00","pubTimestamp":1715090400,"startTime":"0","endTime":"0","summary":"MEXICO CITY, May 7, 2024 /PRNewswire/ -- M8 Pharmaceuticals, anAcino company  announces that the company has signed an exclusive licensing agreement with Supernus Pharmaceuticals, Inc.  , a biopharmaceutical company focused on the development and commercialization of products for the treatment of diseases of the central nervous system , to seek regulatory approval and commercialize Qelbree  under M8's trademark in Latin America.Qelbree  which is approved in the United States is an extended-release formulation of viloxazine, a selective norepinephrine reuptake inhibitor to treat attention deficit hyperactivity disorder  in adults and children 6 years of age and older. Unlike most ADHD medications on the market, this medication is a non-stimulant option.This strategic partnership is aligned with Acino's mission to provide Latin American patients access to innovative medicines and strengthen its leadership position in the central nervous system therapeutic space. The collaboration will pr","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/JRjfPhyunwLj9izACJNRVw--~B/aD0yMjU7dz00MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/prnewswire.com/377e0591f9a784196c597737b36e96ff","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/JRjfPhyunwLj9izACJNRVw--~B/aD0yMjU7dz00MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/prnewswire.com/377e0591f9a784196c597737b36e96ff"],"rights":{"source":"yahoofinance","url":"https://finance.yahoo.com/news/m8-pharmaceuticals-acino-company-signs-140000009.html","rn_cache_url":null,"customStyle":"img, svg { display: none !important; }","selectors":"article","filters":"","directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/m8-pharmaceuticals-acino-company-signs-140000009.html","is_publish_highlight":false,"gpt_icon":0},{"id":"2433478603","title":"Cybin Provides Corporate Update and Highlights Upcoming Clinical Milestones","url":"https://stock-news.laohu8.com/highlight/detail?id=2433478603","media":"Business Wire","top":-1,"share":"https://ttm.financial/m/news/2433478603?lang=en_us&edition=fundamental","pubTime":"2024-05-06 20:32","pubTimestamp":1714998720,"startTime":"0","endTime":"0","summary":"- Recent U.S. $150 Million funding round lead by a syndicate of leading biopharmaceutical institutional investors supports advancement of clinical-stage programs CYB003 and CYB004 -. - Received U.S. Food and Drug Administration  Breakthrough Therapy Designation  for CYB003, a proprietary deuterated psilocybin analog in development for the adjunctive treatment of Major Depressive Disorder  -. - Initiation of pivotal CYB003 Phase 3 study in MDD expected in mid-2024 -. Rapid and large improvements in symptoms of depression after single doses with average 13.75 point difference in MADRS score reduction between CYB003  and placebo at 3 weeks ","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/Sy9aVmeWHj28Z9rQXuHs5w--~B/aD0yNjg7dz00NjA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/business-wire.com/8d98386717c18ce05b1065039a566b5a","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/Sy9aVmeWHj28Z9rQXuHs5w--~B/aD0yNjg7dz00NjA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/business-wire.com/8d98386717c18ce05b1065039a566b5a"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/cybin-provides-corporate-highlights-upcoming-123200530.html","is_publish_highlight":false,"gpt_icon":0},{"id":"2432257323","title":"Busy Philipps Shines Spotlight on ADHD in Women and Shares her Qelbree Story","url":"https://stock-news.laohu8.com/highlight/detail?id=2432257323","media":"GlobeNewswire","top":-1,"share":"https://ttm.financial/m/news/2432257323?lang=en_us&edition=fundamental","pubTime":"2024-05-01 20:00","pubTimestamp":1714564800,"startTime":"0","endTime":"0","summary":"Busy is getting candid about navigating her ADHD diagnosis and treatment experience with Qelbree. The percentage of women newly diagnosed with ADHD between 23-29 and 30-49 years of age nearly doubled in just two years 1. Although symptoms are present in childhood, a significant portion of women with ADHD don’t receive a diagnosis until they are adults2. Busy has been vocal about her personal experience living with ADHD for years, but now she is revealing what it means to be a woman navigating ADHD and wants other women who may be struggling to know they are not alone. Boys are two times more likely than girls to be diagnosed.4 While boys’ symptoms often fit the stereotypical ideas of hyperactive ADHD, girls’ inattentive symptoms are often overlooked. As a result, ADHD often goes undiagnosed in young girls, leading to more adult females being undiagnosed and therefore untreated – a sentiment reflective of Busy’s own experience.2,5","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/rJ24rXQDLktslEmoKvEp8w--~B/aD05Mzt3PTM2NjthcHBpZD15dGFjaHlvbg--/https://media.zenfs.com/en/globenewswire.com/314efe0f659fa701d50fbe1a11762b7a","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/rJ24rXQDLktslEmoKvEp8w--~B/aD05Mzt3PTM2NjthcHBpZD15dGFjaHlvbg--/https://media.zenfs.com/en/globenewswire.com/314efe0f659fa701d50fbe1a11762b7a"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/busy-philipps-shines-spotlight-adhd-120000142.html","is_publish_highlight":false,"gpt_icon":0},{"id":"2432763525","title":"NeuroStar® TMS Advances Treatment for Adolescents During Mental Health Awareness Month","url":"https://stock-news.laohu8.com/highlight/detail?id=2432763525","media":"GlobeNewswire","top":-1,"share":"https://ttm.financial/m/news/2432763525?lang=en_us&edition=fundamental","pubTime":"2024-05-01 12:31","pubTimestamp":1714537860,"startTime":"0","endTime":"0","summary":"The Company is highlighting stories from adolescents with major depressive disorder on the heels of groundbreaking FDA clearanceMALVERN, Pa., May  01, 2024  (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASD","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2024/05/01/2873255/0/en/NeuroStar-TMS-Advances-Treatment-for-Adolescents-During-Mental-Health-Awareness-Month.html","is_publish_highlight":false,"gpt_icon":0},{"id":"2431739388","title":"Intra-Cellular Therapies: Positive MDD Data And Commercial Momentum Make It A Buy","url":"https://stock-news.laohu8.com/highlight/detail?id=2431739388","media":"seekingalpha","top":-1,"share":"https://ttm.financial/m/news/2431739388?lang=en_us&edition=fundamental","pubTime":"2024-04-30 16:38","pubTimestamp":1714466286,"startTime":"0","endTime":"0","summary":"The share price reaction of Intra-Cellular Therapies was not as strong as expected after the positive phase 3 results of Caplyta in major depressive disorder.Positive MDD results represent another de-","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://seekingalpha.com/article/4687414-intra-cellular-therapies-stock-positive-mdd-data-and-commercial-momentum-make-buy","is_publish_highlight":false,"gpt_icon":0},{"id":"2431478330","title":"Why Princeton Professor  rates BlinkLab’s autism & ADHD screening app","url":"https://stock-news.laohu8.com/highlight/detail?id=2431478330","media":"The Market Herald","top":-1,"share":"https://ttm.financial/m/news/2431478330?lang=en_us&edition=fundamental","pubTime":"2024-04-30 13:11","pubTimestamp":1714453860,"startTime":"0","endTime":"0","summary":"In this interview with Sonia Madigan, Professor Sam Wang of Princeton University discusses the development and potential of BlinkLab’s  AI-driven smartphone app, designed to screen for autism and ADHD. He discusses the science behind the MedTech technology; the progress toward obtaining FDA approval; and, the real potential to develop screening for further neurological conditions. Professor Wang also highlights the strategic collaborations with other prestigious academic institutions.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://themarketonline.com.au/why-princeton-professor-rates-blinklabs-autism-adhd-screening-app-2024-04-30/","is_publish_highlight":false,"gpt_icon":0},{"id":"2431682864","title":"Axsome Therapeutics stock rises on upgrade to Overweight at Morgan Stanley","url":"https://stock-news.laohu8.com/highlight/detail?id=2431682864","media":"seekingalpha","top":-1,"share":"https://ttm.financial/m/news/2431682864?lang=en_us&edition=fundamental","pubTime":"2024-04-29 22:08","pubTimestamp":1714399695,"startTime":"0","endTime":"0","summary":"Axsome Therapeutics  has been upgraded to Overweight from Equal-weight by Morgan Stanley banking on positive expected results from a late-stage study of the company’s Alzheimer's disease treatment. Brokerage says, “Based on strong data so far and the similarities in trial design between ADVANCE-1 and ADVANCE-2, we see high odds-of-success for AXS-05 in ADA.” Morgan Stanley has also updated PT from $90 to $115 following revision to their ADA estimates for AXS-05, an increase to peak Auvelity MDD  estimate on account of the strong launch underway and rise in terminal value for AXS-05 in both MDD & ADA based on their increased confidence in Auvelity's IP estate through 2034. “We see a high POS and potential for significant upside from ADVANCE-2, with downside protection provided by currently commercialized CNS therapies,” MS says in a statement on AXSM. AXSM will report its first quarter results next week, with analysts expecting a loss of 1.22 per share on revenue of $73.04M. AXSM is up ","market":"sg","thumbnail":"https://static.seekingalpha.com/cdn/s3/uploads/getty_images/520971174/image_520971174.jpg","type":0,"news_type":0,"thumbnails":["https://static.seekingalpha.com/cdn/s3/uploads/getty_images/520971174/image_520971174.jpg"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://seekingalpha.com/news/4095507-axsome-therapeutics-stock-rises-on-upgrade-to-overweight-at-morgan-stanley","is_publish_highlight":false,"gpt_icon":0},{"id":"2431854199","title":"PHG, IBRX and MESO are among premarket gainers","url":"https://stock-news.laohu8.com/highlight/detail?id=2431854199","media":"seekingalpha","top":-1,"share":"https://ttm.financial/m/news/2431854199?lang=en_us&edition=fundamental","pubTime":"2024-04-29 20:36","pubTimestamp":1714394210,"startTime":"0","endTime":"0","summary":"Gainers: Deciphera Pharmaceuticals  +71%. Koninklijke Philips  +41%. ZyVersa Therapeutics  +36%. HWH International  +16%. NewGenIvf Group  +16%. iClick Interactive Asia Group  +14%. Immunity  +13%. Solowin  +13%. NKGen Biotech  +3% Announces FDA Clearance of Investigational New Drug  Application for SNK01 NK Cell Therapy in Parkinson’s Disease  Fulton Financial  +12% surges after Republic First deal and upgrade at Janney.  Tesla  +11% moment in China helps lift Chinese electric vehicle stocks.  Mesoblast  +9%. WISeKey International  +8% Strengthens Its Strategic Partnership with Swiss Armed Forces in the Space Sector for 2024 and Beyond; Plans Include the Launch of an Enhanced WISeSat Satellite in Q3 2024 Using SpaceX.  Dominos Pizza  +6% rallies after comparable sales growth sizzles in Q1  AGBA Group  +6%. MicroCloud Hologram  +6%. VivoPower International  +6% to sell Kenshaw Electrical  ABVC BioPharma  +6%. WiSA Technologies  +5%. Paramount Global  +5% makes 'best and final' offer fo","market":"sg","thumbnail":"https://static.seekingalpha.com/cdn/s3/uploads/getty_images/522334235/image_522334235.jpg","type":0,"news_type":0,"thumbnails":["https://static.seekingalpha.com/cdn/s3/uploads/getty_images/522334235/image_522334235.jpg"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://seekingalpha.com/news/4095430-phg-ibrx-and-meso-are-among-premarket-gainers","is_publish_highlight":false,"gpt_icon":0},{"id":"2430248695","title":"Promising Outlook for Neurocrine’s NBI-‘845 in MDD Market Based on Strong Phase 2 Results and Competitive Positioning","url":"https://stock-news.laohu8.com/highlight/detail?id=2430248695","media":"TIPRANKS","top":-1,"share":"https://ttm.financial/m/news/2430248695?lang=en_us&edition=fundamental","pubTime":"2024-04-26 15:15","pubTimestamp":1714115723,"startTime":"0","endTime":"0","summary":"Robert W. Baird analyst Brian Skorney has maintained their bullish stance on NBIX stock, giving a Buy rating on April 24. Brian Skorney’s rating is...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/promising-outlook-for-neurocrines-nbi-845-in-mdd-market-based-on-strong-phase-2-results-and-competitive-positioning?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/promising-outlook-for-neurocrines-nbi-845-in-mdd-market-based-on-strong-phase-2-results-and-competitive-positioning?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.abvcpharma.com","stockEarnings":[{"period":"1week","weight":-0.0185},{"period":"1month","weight":-0.0702},{"period":"3month","weight":-0.197},{"period":"6month","weight":0},{"period":"1year","weight":-0.8641},{"period":"ytd","weight":-0.0862}],"compareEarnings":[{"period":"1week","weight":0.0187},{"period":"1month","weight":0.0131},{"period":"3month","weight":0.0392},{"period":"6month","weight":0.1821},{"period":"1year","weight":0.2638},{"period":"ytd","weight":0.0958}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"ABVC BioPharma, Inc., a clinical stage biopharmaceutical company, develops drugs and medical devices to fulfill unmet medical needs in the United States. The company is developing ABV-1501, which is in Phase II clinical trials a combination therapy for triple negative breast cancer; ABV-1504 has completed Phase II clinical trials for major depressive disorders; ABV-1505, which is in Phase II clinical trials for adult attention deficit hyperactivity disorder; ABV-1703, which is in Phase II clinical trials for the treatment of metastatic pancreatic cancer; ABV-1702, which is in Phase II clinical trials to treat myelodysplastic syndromes; ABV-1601 that is in Phase I/II clinical trials for treating depression in cancer patients; ABV-1701 Vitargus that is in Phase II clinical trials for the treatment of retinal detachment or vitreous hemorrhage; and ABV-1519, which is in Phase I/II clinical trials for the treatment of non-small cell lung cancer. ABVC BioPharma, Inc. has a co-development agreement with Rgene Corporation; and collaboration agreements with BioHopeKing Corporation and BioFirst Corporation. The company is based in Fremont, California. ABVC BioPharma, Inc. is a subsidiary of YuanGene Corporation.","yearOnYearQuotes":[{"month":1,"riseRate":0.333333,"avgChangeRate":-0.067297},{"month":2,"riseRate":0,"avgChangeRate":-0.074163},{"month":3,"riseRate":0.666667,"avgChangeRate":0.008224},{"month":4,"riseRate":0.333333,"avgChangeRate":0.005269},{"month":5,"riseRate":0.333333,"avgChangeRate":-0.02728},{"month":6,"riseRate":0.2,"avgChangeRate":1.723479},{"month":7,"riseRate":0.2,"avgChangeRate":-0.153289},{"month":8,"riseRate":0.5,"avgChangeRate":-0.080288},{"month":9,"riseRate":0.166667,"avgChangeRate":-0.101946},{"month":10,"riseRate":0.333333,"avgChangeRate":-0.078089},{"month":11,"riseRate":0.833333,"avgChangeRate":0.1128},{"month":12,"riseRate":0.5,"avgChangeRate":0.000542}],"exchange":"NASDAQ","name":"ABVC BioPharma, Inc.","nameEN":"ABVC BioPharma, Inc."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.22.4","shortVersion":"4.22.4","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"ABVC BioPharma, Inc.(ABVC),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest ABVC BioPharma, Inc.(ABVC) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"ABVC BioPharma, Inc.,ABVC,ABVC BioPharma, Inc.股票,ABVC BioPharma, Inc.股票老虎,ABVC BioPharma, Inc.股票老虎国际,ABVC BioPharma, Inc.行情,ABVC BioPharma, Inc.股票行情,ABVC BioPharma, Inc.股价,ABVC BioPharma, Inc.股市,ABVC BioPharma, Inc.股票价格,ABVC BioPharma, Inc.股票交易,ABVC BioPharma, Inc.股票购买,ABVC BioPharma, Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"ABVC BioPharma, Inc.(ABVC),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest ABVC BioPharma, Inc.(ABVC) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction